Lilly, AstraZeneca, Roche: Oncology's Best Drugs Go First

Why would AstraZeneca pay $2 billion for just 12% of Summit Therapeutics? And why is Lilly's Jaypirca skipping straight to first-line CLL? This week's theme: oncology is done saving its best drugs for later.
In this Monday Morning Oncology Brief, we unpack the three biggest shifts of the week:
🔹 Lilly's Jaypirca (pirtobrutinib) moves to first line in CLL. The FDA approval is backed by an 80% reduction in progression risk versus chemo-immunotherapy in BRUIN CLL-313. It puts pressure on AbbVie's Imbruvica and AstraZeneca's Calquence. But should doctors use their best rescue drug on day one?
🔹 AstraZeneca's $2B Summit deal. A 12% stake de-risks Summit ahead of its November 14 FDA decision and pairs ivonescimab, a PD-1/VEGF bispecific, with AstraZeneca's Claudin 18.2 ADC in GI cancers. A follow-on deal with Daiichi Sankyo extends the strategy to triple-negative breast cancer. Is this AstraZeneca's answer to Merck's Keytruda-plus-ADC playbook?
🔹 Roche's evERA data in the NEJM. Giredestrant + everolimus cut progression risk by 62% in ESR1-mutated ER+/HER2- breast cancer after CDK4/6 inhibitors. It's an all-oral, chemo-free option with no photopsia.
⚡ Rapid fire:
• Lilly exits its Foghorn collaboration on a SMARCA2 degrader.
• Teva wins FDA approval for its Xgeva biosimilar.
• Novocure's tumor-treating fields device gets approved for pancreatic cancer in Japan.
• AstraZeneca and HUTCHMED file savolitinib + Tagrisso in MET-driven lung cancer.
If the best drugs now go first, what happens to the pipeline of second- and third-line rescue therapies?
Subscribe for a new oncology brief every Monday.
#Oncology #CLL #BreastCancer #Pharma #Biotech #AstraZeneca #Lilly #Roche

Chapters:
00:00 Oncology stops saving its best drugs for later
01:09 Lilly's Jaypirca wins frontline FDA approval in CLL
01:41 Superglue vs master key: covalent vs non-covalent BTK inhibitors
02:28 BRUIN CLL-313: 80% lower progression risk vs chemo
03:04 Pressure on AbbVie's Imbruvica and AstraZeneca's Calquence
04:18 The debate: use your best rescue drug on day one?
05:46 AstraZeneca's $2B stake in Summit Therapeutics
06:43 Why a minority stake: de-risking Summit's November FDA decision
07:37 Ivonescimab + Claudin 18.2 ADC: stacking mechanisms in GI cancers
09:09 Taking on Merck's Keytruda + ADC playbook
09:52 Daiichi Sankyo extends the bet to triple-negative breast cancer
10:15 Roche's evERA trial: giredestrant + everolimus
10:57 How oral SERDs shred the estrogen receptor
11:44 62% lower progression risk in ESR1-mutated breast cancer
12:37 No photopsia: Roche's edge over rival oral SERDs
13:53 Rapid fire: Lilly exits Foghorn's SMARCA2 degrader
14:53 Teva's Degevma, a biosimilar to Amgen's Xgeva
15:23 Novocure's tumor-treating fields approved for pancreatic cancer in Japan
16:02 AstraZeneca and HUTCHMED file savolitinib + Tagrisso
16:40 The end of step therapy: what happens to rescue drugs?